AI solutions have proliferated in medical imaging, where ample data is available to train algorithms to detect cancer, stroke and other serious conditions. Lunit’s Insight MMG solution has received 510(k) clearance from the Food and Drug Administration and a CE mark in Europe. Other competitors in the space include iCAD and ScreenPoint Medical.
The prospective study included more than 58,000 women who had regular mammography screenings at Capio Sankt Göran Hospital in Stockholm. Consistent with usual care at the hospital, if any of the readers reported abnormal findings, two radiologists would have a consensus discussion before deciding whether to send patients for additional imaging.
The study found that readings from a radiologist and an AI reader resulted in a 4% increase in screen-detected cancers, or about 11 more cases, compared to two radiologists. However, the AI-radiologist duo also caused a 21% increase in the number of examinations with an abnormal interpretation, resulting in more consensus discussions. This did not translate into an increased recall rate for additional imaging. READ MORE
by Elise Reuter
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.